Friday, 9 June 2017

Cystic fibrosis drug halts lung damage in young children

Orkambi targets the most common mutation for cystic fibrosis, but is not available in the UK on the NHS. Now a trial has shown promising effects in children via New Scientist - Health Read More Here.. Lake forest health and fitness http://ift.tt/2saAqPp

No comments:

Post a Comment